SMSLIFE Stock Overview
Manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
SMS Lifesciences India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,046.10 |
| 52 Week High | ₹1,749.65 |
| 52 Week Low | ₹487.05 |
| Beta | 0.80 |
| 11 Month Change | -30.52% |
| 3 Month Change | -20.02% |
| 1 Year Change | 99.39% |
| 33 Year Change | 26.60% |
| 5 Year Change | 263.80% |
| Change since IPO | 675.75% |
Recent News & Updates
Recent updates
Earnings Working Against SMS Lifesciences India Limited's (NSE:SMSLIFE) Share Price Following 25% Dive
Nov 14
Improved Earnings Required Before SMS Lifesciences India Limited (NSE:SMSLIFE) Stock's 58% Jump Looks Justified
Aug 27Is SMS Lifesciences India (NSE:SMSLIFE) Using Too Much Debt?
Aug 01SMS Lifesciences India Limited (NSE:SMSLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Market
Jun 13SMS Lifesciences India (NSE:SMSLIFE) Use Of Debt Could Be Considered Risky
Feb 10There's Reason For Concern Over SMS Lifesciences India Limited's (NSE:SMSLIFE) Massive 30% Price Jump
Jan 05Should Shareholders Reconsider SMS Lifesciences India Limited's (NSE:SMSLIFE) CEO Compensation Package?
Sep 23SMS Lifesciences India (NSE:SMSLIFE) Is Paying Out A Dividend Of ₹1.50
Sep 07SMS Lifesciences India (NSE:SMSLIFE) Has Affirmed Its Dividend Of ₹1.50
Aug 24SMS Lifesciences India (NSE:SMSLIFE) Will Pay A Dividend Of ₹1.50
Sep 16SMS Lifesciences India (NSE:SMSLIFE) Will Pay A Dividend Of ₹1.50
Sep 02SMS Lifesciences India (NSE:SMSLIFE) Takes On Some Risk With Its Use Of Debt
Jun 03With EPS Growth And More, SMS Lifesciences India (NSE:SMSLIFE) Is Interesting
May 13SMS Lifesciences India's (NSE:SMSLIFE) Solid Profits Have Weak Fundamentals
Nov 23Is Now The Time To Put SMS Lifesciences India (NSE:SMSLIFE) On Your Watchlist?
Jun 21Is SMS Lifesciences India (NSE:SMSLIFE) Using Too Much Debt?
Feb 22SMS Lifesciences India Limited's (NSE:SMSLIFE) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Jan 04Insider Buying: The SMS Lifesciences India Limited (NSE:SMSLIFE) MD & Executive Director Just Bought 19% More Shares
Nov 27Does SMS Lifesciences India (NSE:SMSLIFE) Have A Healthy Balance Sheet?
Nov 24Shareholder Returns
| SMSLIFE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -16.5% | -3.1% | -3.4% |
| 1Y | 99.4% | 41.1% | 27.0% |
Return vs Industry: SMSLIFE exceeded the Indian Pharmaceuticals industry which returned 42.9% over the past year.
Return vs Market: SMSLIFE exceeded the Indian Market which returned 27.5% over the past year.
Price Volatility
| SMSLIFE volatility | |
|---|---|
| SMSLIFE Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: SMSLIFE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SMSLIFE's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 574 | Talluri Veera Venkata Murthy | www.smslife.in |
SMS Lifesciences India Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers APIs in various therapeutic areas, such as anti ulcer, erectile dysfunction, anti gout, anesthesia, anti infective, anti obesity, antifungal, anti convulsant, anti emetic, ophthalmic, anti worm, and antiemetic. It is also developing APIs in the areas of anti depressant, anti psychotic, anti hypertension, veterinary, antiviral, and anticoagulant.
SMS Lifesciences India Limited Fundamentals Summary
| SMSLIFE fundamental statistics | |
|---|---|
| Market cap | ₹3.16b |
| Earnings (TTM) | ₹218.79m |
| Revenue (TTM) | ₹3.18b |
14.5x
P/E Ratio1.0x
P/S RatioIs SMSLIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SMSLIFE income statement (TTM) | |
|---|---|
| Revenue | ₹3.18b |
| Cost of Revenue | ₹2.01b |
| Gross Profit | ₹1.17b |
| Other Expenses | ₹954.14m |
| Earnings | ₹218.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 72.37 |
| Gross Margin | 36.84% |
| Net Profit Margin | 6.87% |
| Debt/Equity Ratio | 44.0% |
How did SMSLIFE perform over the long term?
See historical performance and comparison